Fig. 3.
Competitive binding radioimmunoassay with chCLL-1/GM-CSF and chCLL-1/IL-2. Purified antibody fusion proteins were assayed for their ability to inhibit the binding of 125I-labeled muLym-2 to ARH-77 human myeloma cells. muLym-2 and chLym-1 served as positive and negative controls, respectively.